Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2019

01-10-2019 | Crohn's Disease | Editorial

Is Cannabis of Potential Value as a Therapeutic for Inflammatory Bowel Disease?

Author: Timna Naftali

Published in: Digestive Diseases and Sciences | Issue 10/2019

Login to get access

Excerpt

Cannabis is commonly used by patients with inflammatory bowel disease (IBD) to ameliorate their symptoms. Patients claim that cannabis reduces pain, increases appetite, and reduces the need for other medications [13]. The prevalence of cannabis use in patients with IBD is 15–40% [4], including among pediatric patients [5]. Nevertheless, few scientifically sound data exist regarding the value of cannabis in the treatment of IBD. This discrepancy between the patient’s perception of cannabis as an effective medicine and physician’s reluctance to use non-evidence-based treatment often creates a conflict between patients and physicians, with few IBD patients consulting their medical doctors about cannabis use [6]. More evidence about the value of cannabis as a treatment for inflammatory bowel disease is urgently needed. …
Literature
1.
go back to reference García-Planella E, Marín L, Domènech E, et al. Use of complementary and alternative medicine and drug abuse in patients with inflammatory bowel disease. Med Clin (Barc). 2007;128:45–48. (in Spanish).CrossRef García-Planella E, Marín L, Domènech E, et al. Use of complementary and alternative medicine and drug abuse in patients with inflammatory bowel disease. Med Clin (Barc). 2007;128:45–48. (in Spanish).CrossRef
2.
go back to reference Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:891–896.CrossRefPubMed Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:891–896.CrossRefPubMed
3.
go back to reference RavikoffAllegretti J, Courtwright A, Lucci M, Korzenik JR, Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2809–2814.CrossRef RavikoffAllegretti J, Courtwright A, Lucci M, Korzenik JR, Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2809–2814.CrossRef
4.
go back to reference Ahmed Waseem, Katz Seymour. Therapeutic use of cannabis in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2016;12:668–679. Ahmed Waseem, Katz Seymour. Therapeutic use of cannabis in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2016;12:668–679.
5.
go back to reference Hoffenberg EJ, Newman H, Collins C, Tarbell S, Leinwand K. Cannabis and pediatric inflammatory bowel disease: change blossoms a mile high. J Pediatr Gastroenterol Nutr. 2017;64:265–271.CrossRefPubMedPubMedCentral Hoffenberg EJ, Newman H, Collins C, Tarbell S, Leinwand K. Cannabis and pediatric inflammatory bowel disease: change blossoms a mile high. J Pediatr Gastroenterol Nutr. 2017;64:265–271.CrossRefPubMedPubMedCentral
7.
go back to reference Hanus LO. Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med Res Rev. 2009;29:213–271.CrossRefPubMed Hanus LO. Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med Res Rev. 2009;29:213–271.CrossRefPubMed
8.
go back to reference Morrison PD, Zois V, McKeown DA, et al. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med. 2009;39:1607–1616.CrossRefPubMed Morrison PD, Zois V, McKeown DA, et al. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med. 2009;39:1607–1616.CrossRefPubMed
9.
go back to reference Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015;23:1377–1385.CrossRefPubMed Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015;23:1377–1385.CrossRefPubMed
10.
go back to reference Morgan CJA, Schafer G, Freeman TP, et al. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry J Mental Sci. 2010;197:285–290.CrossRef Morgan CJA, Schafer G, Freeman TP, et al. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry J Mental Sci. 2010;197:285–290.CrossRef
13.
go back to reference Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161–202.CrossRefPubMed Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161–202.CrossRefPubMed
14.
go back to reference Turcotte C, Chouinard F, Lefebvre JS, Flamand N. Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. J Leukoc Biol. 2015;97:1049–1070.CrossRefPubMed Turcotte C, Chouinard F, Lefebvre JS, Flamand N. Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. J Leukoc Biol. 2015;97:1049–1070.CrossRefPubMed
15.
go back to reference McPartland JM, Guy GW, Di Marzo V. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS ONE. 2014;9:e89566.CrossRefPubMedPubMedCentral McPartland JM, Guy GW, Di Marzo V. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS ONE. 2014;9:e89566.CrossRefPubMedPubMedCentral
16.
go back to reference Leinwand KL, Gerich ME, Hoffenberg EJ, Collins CB. Manipulation of the endocannabinoid system in colitis: a comprehensive review. Inflamm Bowel Dis. 2017;23:192–199.CrossRefPubMedPubMedCentral Leinwand KL, Gerich ME, Hoffenberg EJ, Collins CB. Manipulation of the endocannabinoid system in colitis: a comprehensive review. Inflamm Bowel Dis. 2017;23:192–199.CrossRefPubMedPubMedCentral
17.
go back to reference Pi S, Rosenfeld G, Enns R, et al. Patterns and motivations of cannabis use amongst patients with inflammatory bowel disease. GastroHep. 2019;1:100–107.CrossRef Pi S, Rosenfeld G, Enns R, et al. Patterns and motivations of cannabis use amongst patients with inflammatory bowel disease. GastroHep. 2019;1:100–107.CrossRef
18.
go back to reference Weiss A, Friedenberg F. Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend. 2015;1:6–11. Weiss A, Friedenberg F. Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend. 2015;1:6–11.
19.
go back to reference Storr M, Devlin S, Kaplan GG, Panaccione RAC. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20:472–480.CrossRefPubMed Storr M, Devlin S, Kaplan GG, Panaccione RAC. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20:472–480.CrossRefPubMed
21.
go back to reference Stith SS, Vigil JM, Brockelman F, Keeling K, Hall B. The association between cannabis product characteristics and symptom relief. Sci Rep. 2019;9:2712.CrossRefPubMedPubMedCentral Stith SS, Vigil JM, Brockelman F, Keeling K, Hall B. The association between cannabis product characteristics and symptom relief. Sci Rep. 2019;9:2712.CrossRefPubMedPubMedCentral
24.
go back to reference Irving PM, Iqbal T, Nwokolo C, et al. A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis. 2018;24:714–724.CrossRefPubMed Irving PM, Iqbal T, Nwokolo C, et al. A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflamm Bowel Dis. 2018;24:714–724.CrossRefPubMed
Metadata
Title
Is Cannabis of Potential Value as a Therapeutic for Inflammatory Bowel Disease?
Author
Timna Naftali
Publication date
01-10-2019
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2019
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-019-05763-8

Other articles of this Issue 10/2019

Digestive Diseases and Sciences 10/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.